GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE) from its SEC filings: 2025 revenue $116.6 million (+10% vs the year before), net margin 8%, free cash flow -$180,000. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $116.6 million |
| Revenue growth | +10% |
| Net income | $9.9 million |
| Net margin | 8.5% |
| Free cash flow | -$180,000 |
| Diluted EPS | $0.02 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -2% |
| Cash | $43.3 million |
| Long-term debt | $142,000 |
| Share count, 1 year | +16% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.